Long-term outcomes of titanium-nitride-oxide coated stents and drug-eluting stents in acute coronary syndrome: A systematic review and meta-analysis

Table 1 Study characteristics

Study name	Year of publication	Study design	Study location	Sample size	Intervention	Control	Study outcomes	Follow-up duration
TIDE	2011	RCT	Switzerland	302	TiNO-coated stent	Zotarolimus-eluting stent	In-stent late lumen loss; MACE; death; cardiac death; MI; clinically-indicated TLR; clinically-indicated TVR; repeat vascularization; cardiac death or MI; stroke; cardiac death, MI, or clinically indicated TLR	5 years
BASE ACS	2016	RCT	Finland	827	TiNO-coated stent	Everolimus-eluting stent	MACE; cardiac death; non-cardiac death; total death; non-fatal MI; cardiac death or MI; ischemia-driven TLR; DST	5 years (median)
TITAX AMI	2013	RCT	Finland	425	TiNO-coated stent	Paclitaxel-eluting stent	MACE; cardiac death; recurrent MI; cardiac death or recurrent MI; ischemia-driven TLR; DST; all-cause death	5 years
TIDES ACS	2023	RCT	Five European countries	1491	TiNO-coated stent	Everolimus-eluting stent	Cardiac death; MI; ischemia-driven TLR; major bleeding; cardiac death or MI; stent thrombosis; non-cardiac death; all-cause death	5 years

RCT: Randomized controlled trial; TiNO: Titanium-nitride-oxide; MACE: Major adverse cardiovascular event; MI: Myocardial infarction; TLR: Target lesion revascularization; TVR: Target vessel revascularization; DST: Definite stent thrombosis.